Pia Gideon

Chairman.

Pia Gideon has a degree in business administration from the Stockholm School of Economics and has a broad experience from senior positions in global operations, marketing and communication and leadership coaching. Pia also has broad experience of chairman and board assignments in listed, state-owned and start-ups companies, specializing in technology and health healthcare.

Currently on the board of Apoteket, Guard Therapeutics and Gideon & Partners AB. 

Board member since 2009 and chairman of the board since 2018. Holds 25 410 shares through a company controlled by her. 

Independent in relation to the company and its management, independent in relation to the company’s major shareholders. 

Thoas Fioretos

Thoas Fioretos is a professor and chief physician in clinical genetics at Lund University. He specializes in genomics-based precision medicine with a focus on acute leukemia and has published more than 125 scientific articles. Thoas Fioretos has extensive experience in developing new methods for improved clinical diagnostics within cancer based on genetic analyzes. Thoas Fioretos is further founders of Qlucore and Cantargia.

Currently on the board of Cantargia AB and Neodos AB.

Board member since 2007. Holds 184 430 shares. 

Dependent in relation to the company and its management, independent in relation to the company’s major shareholders.

Magnus Fontes

Magnus Fontes has a PHD in Mathematics and has previously been Professor of Mathematics at Lund University and Professor of Bioinformatics at Copenhagen University.

Furthermore, Magnus Fontes has previously been Head of International Relations at the Center for Bioinformatics, Biostatistics and Integrative Biology at Pasteur Institute in Paris. Magnus Fontes has since 2017 has been a leader in Genentech's research efforts in Systems Cancer Immunology. Magnus Fontes has a broad academic experience in applied Mathematics and has been head of the Institute Roche in France since 2020. He is particularly expert in mathematical modeling, statistically learning and bioinformation.

Board member since 2007. Holds 186 460 shares. 

Independent in relation to the company and its management, independent in relation to the company’s major shareholders. 

Carl-Johan Ivarsson

CEO

Carl-Johan Ivarsson has a master's degree in electrical engineering from Lund University and has more than 25 years of experience from software development, product management and sales and has been CEO of Qlucore since 2007. Carl-Johan previously worked for a long time as Vice President with responsibility for product management at Ericsson Mobile Platforms.

Board member since 2007. Holds 346 460 shares and 12 144 warrants.

Dependent in relation to the company and its management, dependent in relation to the company’s major shareholders.

Boel Sundvall

Boel Sundvall has a master's degree in economics from the Stockholm School of Economics. Boel has extensive experience in finance, corporate finance, investor relations and communication and has been a member of group management in several listed global groups.

Currently on the board of EBS Invest AB.

Board member since 2019. Holds 6 500 shares directly and indirectly through a company controlled by her. 

Independent in relation to the company and its management, independent in relation to the company’s major shareholders. 

Helle Fisker

Helle Fisker has a master's degree in Biotechnology and an Executive MBA. Helle has more than 20 years of experience in senior sales and marketing roles in the fields of Medtech and Biotech. She has extensive commercial experience from taking to the global market more than 300 tests for cancer diagnostics, applications for digital Pathology, as well as Oncology treatments and vaccines in Denmark. She is currently working as VP Commercialization for Biovica.

Independent in relation to the company and its management, independent in relation to the company’s major shareholders.